Fully invested in Expertise
Our Team
Launch Therapeutics is backed by leading investors, Carlyle and its life sciences franchise, Abingworth.
Launch Tx was formed in 2022 with the vision of assembling an exceptional team that could redefine late-stage development. The goal? Expediting the pathway for therapies to be approved, and ultimately, delivered to the patients who need them. Meet the team of passionate professionals who are deeply committed to both the science – and the art – of delivering on that promise.
Former CCO and EVP, PPD
Board Director for Saama, TriNetX
Anshul Thakral
Co-Founder, Launch Therapeutics
Chief Executive Officer
Previously SVP of Development Operations, PPD
Elisha Talley-Roithner
Head of Operations
Previously VP of Clinical Development, BeiGene
Shao Chang, MD, PhD
Chief Medical Officer
Previously Chief of Regulatory Affairs with EQRX
Michael Doherty
Chief Regulatory Officer
Previously CEO, Immune Design
Carlos Paya, MD, PhD
Head of R&D
Previously VP of Development Operations, PPD
Matthew Cramblett
Head of Clinical Operations
Previously Head of Partnership Excellence, PPD
Laura Batchelor
Head of Alliance Management
Previously CBO, Nuvelution
James Cornwall, PhD
Head of Business Development
Previously Global Head of Biostatistics, ICON
Aaron Camp
Head of Biometrics
David Simmons
Chairman of the Board
Kurt von Emster, CFA
Co-Founder, Launch Therapeutics
Managing Partner and Head of Abingworth Life Sciences, Abingworth
Steve Wise
Managing Director & Global Head of Healthcare, Carlyle
Joe Bress
Managing Director, Carlyle
Bali Muralidhar
Managing Partner, Chief Investment Officer & COO, Abingworth
Anshul Thakral
Co-Founder, Launch Therapeutics
Chief Executive Officer
David Simmons
Former Chairman & CEO, PPD
William Sharbaugh
Former President & COO, PPD
Ian Read
Former Chairman & CEO, Pfizer
Laura Hamill
Former EVP, Worldwide Commercial Operations, Gilead
Scott Brun
Former VP, Scientific Affairs & Head of AbbVie Ventures, AbbVie
Together, We Deliver Excellence
A powerhouse of seasoned industry experts, the Launch Tx leadership team has achieved remarkable milestones and driven groundbreaking studies. Let's break it down by the numbers:
396+
Phase 3 studies
165+
years in drug development
leadership roles
95+
assets brought to market